- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04333472
Piclidenoson for Treatment of COVID-19
Piclidenoson for Treatment of COVID-19 - A Randomized, Double-Blind, Placebo-Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blind, placebo-controlled, pilot trial of piclidenoson 2 mg Q12H added to SSC, compared to placebo plus SSC, in a population of hospitalized subjects with "Moderate" or "Severe" COVID-19 per U.S. National Institutes of Health (NIH) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines (2020). Subjects will be randomized according to a 1:1 ratio to one of the trial arms, and treated for up to 28 days, at the discretion of the Investigator. Piclidenoson 2 mg and placebo are supplied as matching tablets for oral administration.
Following initial diagnosis of COVID-19, and after having provided informed consent, subjects will be randomized according to 1:1 ratio to one of the trial arms on Day 0. SSC will be implemented and documented for all subjects, and maintained throughout the treatment period.
Vital signs (temperature, blood pressure, pulse rate per minute, respiratory rate per minute, oxygen saturation (SpO2), and PaO2/FiO2) of subjects will be monitored twice daily according to SSC. Parameters of clinical, respiratory, and vital status will be collected daily. Viral shedding will be assessed on a regular basis. Samples for pharmacokinetic (PK) analysis will be collected on Day 4.
Efficacy of piclidenoson will be assessed by clinical, respiratory, and virologic parameters. Safety and tolerability of piclidenoson will be assessed by adverse event (AE) monitoring, vital signs assessment, electrocardiograms (ECGs), and clinical laboratory tests (complete blood count (CBC) and extended chemistry panel). Adverse events will be graded by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria
- II Multiprofile Hospital for Active Treatment - Sofia EAD
-
Sofia, Bulgaria
- IV Multiprofile Hospital for Active Treatment - Sofia EAD
-
-
-
-
-
Jerusalem, Israel
- Hadassah medical Center
-
Jerusalem, Israel
- Shaare Zedek Medical Center
-
-
-
-
-
Iaşi, Romania
- Clinical Hospital for Infectious Diseases "St. Parascheva" Iasi
-
Suceava, Romania
- "Sfantul Ioan cel Nou" County Emergency Hospital Suceava
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Hospitalized subjects 18 to 85 years of age, inclusive
- Able and willing to sign informed consent
- Molecular (RT-PCR) diagnosis of SARS-CoV-2 infection
Moderate or Severe illness per NIH COVID-19 Treatment Guidelines:
"Moderate" Illness:
- Symptoms such as cough, fever, sore throat, malaise, myalgias, headache; and
- Evidence of lower respiratory tract disease by clinical assessment and/or imaging; and
- SpO2 >93% on room air at sea level
"Severe" Illness, including any of the following:
- Respiratory rate >30 breaths/minute; or
- SpO2 ≤93% on room air at sea level; or
- Ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300; or
- Lung infiltrates >50% of pulmonary volume on imaging
- Female subjects must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of investigational product
Female subjects of childbearing potential and male subjects with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female subjects of childbearing potential are all those except subjects who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal.
For females: 2 of the following contraceptive methods, with at least 1 being a barrier method:
- Hormonal contraceptives for at least 27 days before dosing
- Intrauterine device (IUD) in place at least 27 days before dosing
- Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening
- Surgical sterilization of the partner (vasectomy at least 1 month before screening)
- Female subjects must have a negative urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) within 24 hours prior to the start of investigational product.
- For males: Surgical sterilization (vasectomy at least 1 month before screening) or double barrier methods.
Exclusion Criteria
1. "Critical" Illness, per NIH COVID-19 Treatment Guidelines, including any of the following:
- Respiratory failure; or
- Septic shock; or
- Multiple organ dysfunction
- Subjects who require mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
- Participation in another clinical trial concurrently
- Concurrent treatment with immunomodulators or anti-rejection drugs
- Nursing women, pregnant women, women of childbearing potential who do not want adequate contraception
History of any of the following diseases or conditions:
- Advanced or decompensated liver disease (including presence or history of bleeding varices, ascites, encephalopathy, or hepato-renal syndrome)
- Inability to swallow tablets, or gastrointestinal disease which could interfere with the absorption of piclidenoson
- Any malignancy within 5 years before screening; exceptions are superficial dermatologic malignancies (e.g., squamous cell or basal cell skin cancer treated with curative intent)
- Cardiomyopathy, significant ischemic cardiac or cerebrovascular disease (including history of angina, myocardial infarction, or interventional procedure for coronary artery disease), or cardiac rhythm disorder
- QTcF interval on an average of triplicate ECGs >450 milliseconds (msec) for males or >470 msec for females (except when QT prolongation is associated with right or left bundle branch block, in which case enrollment is allowed)
- Any condition which increases proarrhythmic risk, including hypokalemia, hypomagnesemia, congenital Long QT Syndrome
- Ongoing or planned use of a concomitant medication that is on the CredibleMeds list of drugs known to cause Torsades de Pointes unless the subject can be screened and monitored under the guidelines proposed by Giudicessi (2020)
- Pancreatitis
- Severe or uncontrolled psychiatric disorder, e.g., depression, manic condition, psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and relapse of substance abuse
- Active seizure disorder defined by either an untreated seizure disorder or continued seizure activity within the preceding year despite treatment with anti-seizure medication
- Bone marrow or solid organ transplantation
- Any serious condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed
Any of the following abnormal laboratory tests:
- Platelet count <90,000 cells/mm3
- Absolute neutrophil count (ANC) <1,500 cells/mm3
- Estimated creatinine clearance (CrCl) <50 mL/min by Cockroft-Gault formulation
- Bilirubin level ≥2.5 mg/dL unless due to Gilbert's syndrome
- AST or ALT level ≥3X the upper limit of normal
- Serum albumin level <3.0 g/dL
- International normalized ratio (INR) ≥1.5 (except subjects maintained on anticoagulant medications)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Piclidenoson
Piclidenoson 2 mg every 12 hours orally added to standard of care
|
Piclidenoson 2 mg orally every 12 hours for up to 28 days
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Placebo every 12 hours orally added to standard of care
|
Placebo orally every 12 hours for up to 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects alive and free of respiratory failure
Time Frame: 29 days
|
Proportion of subjects alive and free of respiratory failure (defined as need for non-invasive or invasive mechanical ventilation, high-flow oxygen, or extracorporeal membrane oxygenation) at Day 29
|
29 days
|
Proportion of subjects discharged home alive
Time Frame: 29 days
|
Proportion of subjects alive and discharged to home without need for supplemental oxygen at Day 29
|
29 days
|
Treatment-emergent adverse events (AEs)
Time Frame: 29 days
|
Proportion of patients experiencing AEs
|
29 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical status
Time Frame: 29 days
|
• Clinical status at Day 29 on NIAID 8-point ordinal scale (NIH 2020):
|
29 days
|
Time to improvement
Time Frame: 29 days
|
Time (days) to improvement of 2 points on 7-point ordinal clinical scale
|
29 days
|
Incidence of mechanical ventilation
Time Frame: 29 days
|
Proportion of patients who require mechanical ventilation
|
29 days
|
Ventilator-free days
Time Frame: 29 days
|
Ventilator-free days to Day 29
|
29 days
|
Incidence of Intensive Care Unit (ICU) admission
Time Frame: 29 days
|
Proportion of patients who require ICU admission
|
29 days
|
Duration of ICU stay
Time Frame: 29 days
|
Duration (days) of ICU stay
|
29 days
|
Time to hospital discharge
Time Frame: 29 days
|
Time (days) to hospital discharge
|
29 days
|
Duration of need for supplemental oxygen
Time Frame: 29 days
|
Duration (days) of need for supplemental oxygen
|
29 days
|
Time to virus negativity
Time Frame: 29 days
|
Time (days) to virus negativity by RT-PCR, defined as absence of SARS CoV 2 on 2 consecutive days of sampling
|
29 days
|
SARS-CoV-2 viral load
Time Frame: 29 days
|
SARS-CoV-2 viral load (number of copies) by quantitative RT-PCR
|
29 days
|
AEs leading to withdrawal
Time Frame: 29 days
|
Proportion of patients experiencing AEs leading to early discontinuation of trial treatment
|
29 days
|
Treatment-emergent serious AEs (SAEs)
Time Frame: 29 days
|
Proportion of patients experiencing SAEs
|
29 days
|
Treatment-emergent abnormalities in clinical laboratory parameters or electrocardiograms (ECGs)
Time Frame: 29 days
|
Proportion of patients experiencing treatment-emergent changes in clinical laboratory parameters or ECGs
|
29 days
|
Incidence of meeting safety-related stopping rules
Time Frame: 29 days
|
Proportion of patients who meet study safety-related stopping rules
|
29 days
|
Pharmacokinetics of piclidenoson in this patient population
Time Frame: 5 days
|
Plasma concentrations over time of piclidenoson
|
5 days
|
Serum cytokine levels
Time Frame: 29 days
|
Change from baseline in serum concentrations of cytokines
|
29 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Zivit Harpaz, Can-Fite BioPharma Ltd
Publications and helpful links
General Publications
- Fishman P, Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol. 2016 Sep;35(9):2359-62. doi: 10.1007/s10067-016-3202-4. Epub 2016 Feb 17.
- Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Des Devel Ther. 2019 Jan 30;13:491-497. doi: 10.2147/DDDT.S195294. eCollection 2019.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CF101-241COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
Clinical Trials on Piclidenoson
-
Can-Fite BioPharmaCompletedKeratoconjunctivitis SiccaIsrael